131 related articles for article (PubMed ID: 37226898)
1. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
[TBL] [Abstract][Full Text] [Related]
3. Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Strouse JJ; Spevak M; Mack AK; Arceci RJ; Small D; Loeb DM
Pediatr Blood Cancer; 2005 Apr; 44(4):407-11. PubMed ID: 15602719
[TBL] [Abstract][Full Text] [Related]
4. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
5. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series.
Ryan A; Tawagi K; VanderVeen N; Matrana M; Vasquez R
Clin Genitourin Cancer; 2021 Dec; 19(6):e395-e400. PubMed ID: 34565708
[TBL] [Abstract][Full Text] [Related]
7. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
[TBL] [Abstract][Full Text] [Related]
9. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
[TBL] [Abstract][Full Text] [Related]
10. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
[TBL] [Abstract][Full Text] [Related]
11. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
Lockhart AC; Bauer TM; Aggarwal C; Lee CB; Harvey RD; Cohen RB; Sedarati F; Nip TK; Faessel H; Dash AB; Dezube BJ; Faller DV; Dowlati A
Invest New Drugs; 2019 Feb; 37(1):87-97. PubMed ID: 29781056
[TBL] [Abstract][Full Text] [Related]
12. Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia.
Guo N; Azadniv M; Coppage M; Nemer M; Mendler J; Becker M; Liesveld J
Transl Oncol; 2019 Apr; 12(4):602-613. PubMed ID: 30699367
[TBL] [Abstract][Full Text] [Related]
13. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Walsh A; Kelly DR; Vaid YN; Hilliard LM; Friedman GK
Pediatr Blood Cancer; 2010 Dec; 55(6):1217-20. PubMed ID: 20979179
[TBL] [Abstract][Full Text] [Related]
14. Pevonedistat Suppresses Pancreatic Cancer Growth
Xu J; Li Z; Zhuo Q; Ye Z; Fan G; Gao H; Ji S; Yu X; Xu X; Liu W; Xu W
Front Oncol; 2022; 12():822039. PubMed ID: 35155257
[TBL] [Abstract][Full Text] [Related]
15. Targeting neddylation pathway with MLN4924 (Pevonedistat) induces NOXA-dependent apoptosis in renal cell carcinoma.
Wang J; Wang S; Zhang W; Wang X; Liu X; Liu L; Li L; Liang Y; Yu J; Jeong LS; Jia L; Zhao H; Zhang Y
Biochem Biophys Res Commun; 2017 Sep; 490(4):1183-1188. PubMed ID: 28669728
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
Beckermann KE; Jolly PC; Kim JY; Bordeaux J; Puzanov I; Rathmell WK; Johnson DB
J Immunother Cancer; 2017; 5():1. PubMed ID: 28105368
[TBL] [Abstract][Full Text] [Related]
17. Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma.
Torka P; Mavis C; Kothari S; Belliotti S; Gu J; Sundaram S; Barth M; Hernandez-Ilizaliturri FJ
EJHaem; 2020 Jul; 1(1):122-132. PubMed ID: 33073261
[TBL] [Abstract][Full Text] [Related]
18. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib.
Lee AQ; Ijiri M; Rodriguez R; Gandour-Edwards R; Lee J; Tepper CG; Li Y; Beckett L; Lam K; Goodwin N; Satake N
Front Oncol; 2021; 11():648097. PubMed ID: 33842362
[TBL] [Abstract][Full Text] [Related]
19. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
20. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
